Advanced Prostate Cancer Consensus Conference

Advanced Prostate Cancer
Consensus Conference: APCCC 2019

29-31 August 2019, Basel/Switzerland

APCCC - Structure and Definitions

The APC Society

The APC society is a non-profit organisation with the aim to improve the treatment and care of men with advanced prostate cancer. The APC Society organises the Advanced Prostate Cancer Consensus Conference (APCCC). The APC Society is the legal representative of APCCC in Switzerland.


APCCC in general

In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that are also costly and potentially toxic. Further developments such as novel next-generation imaging methods, biomarkers, molecular characterization and genetics lead to many areas with open questions and lack or low level of evidence.  

The Advanced Prostate Cancer Consensus Conference (APCCC) was initiated to provide a forum for discussion and debates on current management options for men with advanced prostate cancer in these unclear situations. Two days of the conference are dedicated to high-level presentations, discussions and debates, summarizing and conceptualizing the available literature and evidence.

The conference concludes with voting by the panel on pre-defined consensus questions, targeting areas of clinical relevance. Following the conference a manuscript with containing the expert recommendations is published in a peer reviewed journal (2015 Annals of Oncology, 2017 European Urology).

Aims of APCCC

  • Provide an update on the current standard of advanced prostate cancer management with a focus on situations with no high level evidence for a specific treatment option.
  • Advanced prostate cancer is defined by APCCC as locally advanced disease and men with biochemical recurrence or metastatic disease.
  • Program is highly educational, consisting of invited lectures, debates and discussions led by the panel of international and interdisciplinary prostate cancer experts.
  • The entire conference is focused on “knowledge translation” by summarising and conceptualising the current standards of advanced prostate cancer management and disseminating the results of the consensus discussions and votings.
  • The conference will culminate with an interdisciplinary expert consensus panel meeting that will discuss and vote on predefined questions relating to key areas where there is lack of evidence or conflict regarding the optimal treatment of men with advanced prostate cancer. The process of the conference and the development of the questions have been described in detail (Ref APCCC 2015 und APCCC 2017).
  • Participants will be able to attend the two days of the discussions as well as the voting of the panellists as part of the conference.
  • The consensus summary is published after the meeting in a high impact medical journal.
  • Attendees will be able to interact with panel members, facilitating and encouraging international collaboration.


Scientific Committee

The scientific committee is formed by international prostate cancer experts. The tasks of the scientific committee are:

  • Selection of topics for the APCCC
  • Selection of the expert panellist for the APCCC
  • Co-authors on APCCC manuscript
  • Scientific supervision of  post-APCCC satellite meetings


Expert Consensus Panel

The panel for APCCC consists of multidisciplinary cancer physicians and scientists selected based on their academic track record and involvement in clinical or translational research in the field of advanced prostate cancer.

Panellists should be actively seeing men with advanced prostate cancer for discussion of management recommendations on a regular basis.

The panellists will vote on the consensus questions at the end of the APCCC conference. After the conference the panellists will co-author the APCCC manuscript.

Geographic representation is considered important; therefore experts may be invited as part of the panel even if their academic track record is not equal to some experts from highly academic centres.

From one APCCC to the next about 20% of the panellists are substituted. Panel members who have paused for one APCCC may be part of one of the following conferences again.


APCCC Advisory Committee

The APCCC advisory committee is formed of non-voting panellist and other experts including patient advocates and delegates important for APCCC.

Non-voting APCCC panellists are experts who are not involved in clinical management and decision making (e.g. radiologists, pathologists, epidemiologists and statisticians). Non-voting panellists are co-authors on the APCCC manuscript.

Delegates of organisations e.g. Movember or Prostate Cancer Foundation and patient advocates can be part of the APCCC advisory committee.



The summary of the APCCC results including the questions and voting results is published shortly after the conference in a peer reviewed journal. The journal is chosen by the scientific committee. Due to the fact that advanced prostate cancer is treated in many countries by urologists, clinical oncologists or medical oncologists the target journal has to have a wide readership.


Re-use of APCCC questions in APCCC Satellite meetings

APCCC satellite meetings are encouraged for country-specific or regional educational purposes.

In order to receive the APCCC logo/stamp, the satellite meetings must:

  • Be approved by the APC Society (through an application for endorsement)
  • Be sponsored by more than one industry partner
  • Involve at least one member of the scientific committee or the panel of APCCC
  • If the APCCC questions are used, they have to be used in the original format and cannot be changed. Questions can be selected depending on specific needs.
  • For purely academic purposes the re-use of the questions is free of charge, for meetings involving industry sponsoring a financial contribution towards the APC Society has to be paid.